Almarai signs deal to provide medication for children with rheumatism

SAUDI ARABIA – Almarai Company has signed an agreement with the Charitable Association for Rheumatism Patients to provide essential medications for children diagnosed with rheumatism.

The agreement is designed to help improve the health of affected children, strengthen their quality of life, and reduce the complications that arise when access to essential medical care is limited.

The partnership will run for a full year, directing support to children with limited access to long-term treatment.

Through this initiative, children will continue receiving the medications they rely on, support that helps improve their health, enhances their daily lives, and reduces the risk of complications over time.

Rheumatism is a chronic condition that can limit mobility and overall quality of life when its symptoms and complications are not properly managed.

With a strong belief in the private sector’s role in driving sustainable social impact, Almarai launched this initiative in partnership with the Association to ensure that support reaches the children who need it most.

The agreement comes in line Almarai’s efforts and initiatives aiming to improve well being of children. Healthcare remains one of the company’s priority areas within its social responsibility programs, alongside several other key developmental fields.

Recently, the company appointed Fawaz bin Mohammed Al-Jasser as its new Chief Executive Officer, who succeed Abdullah bin Nasser Albader, who resigned from the position citing personal reasons. 

Al-Jasser brings nearly 20 years of experience within Almarai, having held senior leadership roles across multiple divisions, including bakery, seafood and human resources.  

He also served as general manager of Teeba Company, the group’s subsidiary in Jordan. Al-Jasser holds a postgraduate degree in Business Administration from the University of Leicester. 

The leadership change comes as the Saudi Arabian food-and-beverage group continues to deliver steady financial results.

For the quarter ending 30 September, 2025,  Almarai reported sales of SR5.55 billion (US$1.47 billion), a 6.6% increase compared with the same period last year.  

The company attributed the growth to strong performance across its major markets and channels, supported by higher volumes in poultry, dairy, food and bottled water. 

Gross profit for the period rose 4.6% to SR1.74 billion (US$463.62M), while operating profit increased 2% to SR757.27 million (US$201.78M).

Net profit reached SR613.2 million (US$163.39M), marking a 7.5% rise year-on-year, which the company linked to disciplined cost control, a favourable product mix and lower funding costs. 

To receive our email newsletters with the latest news and insights from Africa, the Middle East and around the world, SUBSCRIBE HERE